Regimens containing macrolides (azithromycin) showed no clear difference in adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing tetracycline (doxycycline) (low certainty).
Macrolides showed no clear difference in clinical cure: syndromic approach compared with any other antibiotic (low certainty).
Macrolides showed no clear difference in clinical cure: aetiological approach compared with any other antibiotic (low certainty).
It is very uncertain whether macrolides changes clinical improvement: syndromic approach compared with any other antibiotic (very low certainty).
Macrolides showed no clear difference in clinical improvement: aetiological approach compared with any other antibiotic (low certainty).
Macrolides showed no clear difference in microbiological cure compared with any other antibiotic (low certainty).
It is very uncertain whether macrolides changes minor adverse events compared with any other antibiotic (very low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
It is very uncertain whether macrolides changes treatment failure compared with doxycycline (very low certainty).
It is very uncertain whether macrolides changes resolution of fever within 48 hours compared with doxycycline (very low certainty).
Macrolides showed no clear difference in resolution of fever within 5 days compared with doxycycline (low certainty).
Macrolides probably leads to lower ≥ 1 exacerbation compared with placebo (moderate certainty).